Part,  Chapter, Paragraph

 1   II,     5.  5.  1|     project. Acta Psychiatr Scand 109 (suppl 420):47-54.~ ~Alonso
 2   II,     5.  5.  3|          study. Acta Neurol Scand 109:378-384.~De Sã J, Paulos
 3   II,     5.  5.  3|       criteria. Acta Neurol Scand 109:385-389.~Firnhaber W, Lauer
 4   II,     5.  5.  3|          179 PD-patients of which 109 were treated with levodopa
 5   II,     5.  8.  7| co-morbidity. Respir Res 2006; 7: 109-116.~ ~Halbert RJ, Isonaka
 6   II,     5. 10.  7|           of the European Union L 109, 6.5.2000, pp. 29–42.~htt ~ ~
 7   II,     5. 11.  7|           J Dermatol 1993;129:101-109.~ ~Williams HC, Strachan
 8   II,     5. 12.  7|            Int J Epidemiol 26:100-109.~ ~Corrao G, Aricò S (1998):
 9   II,     9.  1.  1|      multicentre study. Bjog 2002;109(7):740-5.~ ~Escobar GJ,
10   II,     9.  1.  1|        The Netherlands. Bjog 2002;109(2):212-3.~ ~Wood NS, Marlow
11   II,     9.  3.  2|      multicentre study. Bjog 2002;109(7):740-5.~ ~Escobar GJ,
12   II,     9.  3.  2|        The Netherlands. Bjog 2002;109(2):212-3.~ ~Wood NS, Marlow
13  III,    10.  2.  1|      Public Health Vol. 14(2):103-109.~ ~Greyling T et al. (2002):
14  III,    10.  2.  1|    foodstuffs. Official Journal L 109 , 06/05/2000 P. 0029 – 0042 [
15  III,    10.  4.  2|        European Communities No. L 109, 6 May 2000. Available at:~htt ~ ~
16  III,    10.  5.  2|         General Practice; 56: 104–109.~ ~Verheij RA et al. (1998):